Response-adaptive randomization with imperfect intermediate endpoints
Clinical Trials · 2026
DOI: 10.1177/17407745261415792 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Trials, 2026. Verfasst von Yousra Kherabi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Infectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. Hauptthemen laut MEDLINE: Endpoint Determination, Antitubercular Agents, Research Design, Tuberculosis. Die Arbeit nennt 26 Literaturangaben. Gefördert von: société de pathologie infectieuse de langue française, agence régionale de santé îledefrance, Monahan Foundation.
Abstract (Originalsprache)
Background
Response-adaptive randomization is controversial even in the best circumstances when based on a quickly determined primary outcome. In disease settings in which the primary outcome requires long follow-up, an intermediate endpoint may be chosen to update randomization allocations. The aim of our study is to evaluate the impact of response-adaptive randomization applied to an imperfect intermediate endpoint. We use tuberculosis trials as the motivating example.
Methods
We simulated a response-adaptive randomization design, adapting randomization allocations using an imperfect intermediate endpoint, in a superiority trial of two experimental regimens and one control arm. The primary study outcome was treatment success after 73 weeks from randomization; the intermediate endpoint was culture conversion at 8 weeks. We compared different sensitivity (Se) and specificity (Spe) scenarios for the intermediate endpoint, while varying the true treatment efficacy. We evaluated the performance of response-adaptive randomization to achieve its primary goal of allocating more participants to the better arm and the impact of time-trends on type I error rate.
Results
Even in an ideal state of perfect accuracy (i.e. intermediate endpoint with Se = 100% and Spe = 100%), response-adaptive randomization did not always live up to its main purpose of allocating more patients to the better arm. Lower accuracy of the intermediate endpoint leads to greater divergence from the goal of more allocations to the better arm. The larger the difference in treatment efficacy between the arms, the more striking the impact of an intermediate endpoint with poor diagnostic accuracy. Time-trends inflate the type I error rate, and while stratified tests can correct this, they do so at the cost of a power loss. Allocating more patients to the worst arm increases power for comparisons with this arm but reduces power for comparisons of the best arm to control.
Conclusion
Given the objective of evaluating several new therapeutic regimens in a timely manner, response-adaptive randomization is tempting. However, it requires at least reliance on highly accurate intermediate endpoints, which are still no guarantee of response-adaptive randomization’s trustworthiness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
- Université Paris Cité and Université Sorbonne Paris Nord, INSERM, IAME, Paris, France.
- Clinical Trials Research and Statistics Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.
- Office of Biostatistics Research, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.
ORCID-Profile: Yousra Kherabi, Michael A Proschan
Förderung
- société de pathologie infectieuse de langue française
- agence régionale de santé îledefrance
- Monahan Foundation
- Association de Chimiothérapie AntiInfectieuse
- Fulbright France
Zitieren
APA
Kherabi, Y., Proschan, M. A., & Dodd, L. E. (2026). Response-adaptive randomization with imperfect intermediate endpoints. Clinical Trials. https://doi.org/10.1177/17407745261415792
Vancouver
Kherabi Y, Proschan MA, Dodd LE. Response-adaptive randomization with imperfect intermediate endpoints. Clinical Trials. 2026. doi:10.1177/17407745261415792
BibTeX
@article{Kherabi2026,
author = {Kherabi, Yousra and Proschan, Michael A and Dodd, Lori E},
title = {Response-adaptive randomization with imperfect intermediate endpoints},
journal = {Clinical Trials},
year = {2026},
doi = {10.1177/17407745261415792}
}
EUVIMED